ECSP003652A - TRATAMIENTO DE COMBINACION CON I1-1ra Y COMPUESTOS QUE INHIBEN EL PROCESAMIENTO Y LA LIBERACION DE I1-1 - Google Patents

TRATAMIENTO DE COMBINACION CON I1-1ra Y COMPUESTOS QUE INHIBEN EL PROCESAMIENTO Y LA LIBERACION DE I1-1

Info

Publication number
ECSP003652A
ECSP003652A EC2000003652A ECSP003652A ECSP003652A EC SP003652 A ECSP003652 A EC SP003652A EC 2000003652 A EC2000003652 A EC 2000003652A EC SP003652 A ECSP003652 A EC SP003652A EC SP003652 A ECSP003652 A EC SP003652A
Authority
EC
Ecuador
Prior art keywords
release
combination
processing
inhibit
compounds
Prior art date
Application number
EC2000003652A
Other languages
English (en)
Inventor
Joseph Tardio
Paul Hadvary
Hans Lengsfeld
Hans Steffen
Bruce Henry Littman
Marcel Schmid
Farland Small Donald Mac
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP003652A publication Critical patent/ECSP003652A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El invento se refiere a métodos y composiciones para tratar y prevenir estados de enfermedad por la interleuquina 1 (IL-1). En los métodos y las composiciones se usa un polipáptido antagonista del receptor de la interleuquina 1(I1-1ra.), o una variante del mismo, en combinación con un agente no esteroide que inhibe el procesamiento y la liberación del I1-1.
EC2000003652A 1999-09-14 2000-09-12 TRATAMIENTO DE COMBINACION CON I1-1ra Y COMPUESTOS QUE INHIBEN EL PROCESAMIENTO Y LA LIBERACION DE I1-1 ECSP003652A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15401099P 1999-09-14 1999-09-14

Publications (1)

Publication Number Publication Date
ECSP003652A true ECSP003652A (es) 2002-04-23

Family

ID=22549650

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2000003652A ECSP003652A (es) 1999-09-14 2000-09-12 TRATAMIENTO DE COMBINACION CON I1-1ra Y COMPUESTOS QUE INHIBEN EL PROCESAMIENTO Y LA LIBERACION DE I1-1

Country Status (13)

Country Link
EP (1) EP1214087A1 (es)
JP (1) JP2003509378A (es)
AR (1) AR033650A1 (es)
AU (1) AU6464400A (es)
BR (1) BR0014003A (es)
CA (1) CA2383026A1 (es)
CO (1) CO5190701A1 (es)
EC (1) ECSP003652A (es)
GT (1) GT200000155A (es)
PA (1) PA8502901A1 (es)
PE (1) PE20010685A1 (es)
TN (1) TNSN00183A1 (es)
WO (1) WO2001019390A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57852B1 (sr) 2004-04-02 2018-12-31 Swedish Orphan Biovitrum Ab Publ Postupci za smanjenje agregacije il-1ra
WO2008129288A2 (en) * 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides useful in the treatment of inflammation
MA47440B1 (fr) * 2015-02-16 2021-08-31 The Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy & Undiv Sulfonylurées, composés apparentés, et leur utilisation
AU2017219204A1 (en) 2016-02-16 2018-08-23 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Sulfonylureas and related compounds and use of same
EP3445757B1 (en) * 2016-04-18 2020-11-25 Novartis Inflammasome Research, Inc. Compounds and compositions for treating conditions associated with nlrp activity
AU2018210525B2 (en) 2017-01-23 2022-06-02 Genentech, Inc. Chemical compounds as inhibitors of interleukin-1 activity
CA3059458A1 (en) 2017-05-24 2018-11-29 The University Of Queensland Novel compounds and uses
WO2018225018A1 (en) 2017-06-09 2018-12-13 Cadila Healthcare Limited Novel substituted sulfoximine compounds
EP3978489A1 (en) 2017-07-07 2022-04-06 Inflazome Limited Novel sulfonamide carboxamide compounds
EP3649112A1 (en) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
CU24615B1 (es) 2017-07-24 2022-07-08 Novartis Ag Compuestos para tratar afecciones asociadas con la actividad nlrp
UY37848A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
CA3071150A1 (en) * 2017-08-15 2019-02-21 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
EP3668840A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
KR20200041337A (ko) 2017-08-15 2020-04-21 인플라좀 리미티드 신규한 설폰아마이드 카복스아마이드 화합물
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
WO2019068772A1 (en) 2017-10-03 2019-04-11 Inflazome Limited NEW COMPOUNDS
AU2018363771A1 (en) 2017-11-09 2020-05-14 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019166628A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
EP3759077A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
EP3759103A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
WO2019166627A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
GB201806578D0 (en) * 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
EP3817817A1 (en) 2018-07-03 2021-05-12 Novartis AG Nlrp modulators
AU2019305095A1 (en) 2018-07-20 2020-12-17 F. Hoffmann-La Roche Ag Sulfonylurea compounds as inhibitors of interleukin-1 activity
US20230011652A1 (en) 2018-10-24 2023-01-12 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
MX2021008426A (es) 2019-01-14 2021-09-23 Cadila Healthcare Ltd Nuevos derivados de sulfonilurea sustituida.
WO2021237891A1 (en) * 2020-05-25 2021-12-02 Beijing Vdjbio Co., Ltd. An interleukin-1 receptor antagonist and a fusion protein containing the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
KR100324058B1 (ko) * 1997-01-29 2002-02-16 디. 제이. 우드, 스피겔 알렌 제이 술포닐 우레아 유도체 및 인터루킨-1 활성 조절에서의 그의 용도
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins

Also Published As

Publication number Publication date
PE20010685A1 (es) 2001-07-03
CA2383026A1 (en) 2001-03-22
GT200000155A (es) 2002-03-08
JP2003509378A (ja) 2003-03-11
WO2001019390A1 (en) 2001-03-22
AU6464400A (en) 2001-04-17
BR0014003A (pt) 2002-05-21
EP1214087A1 (en) 2002-06-19
TNSN00183A1 (fr) 2005-11-10
PA8502901A1 (es) 2002-02-21
CO5190701A1 (es) 2002-08-29
AR033650A1 (es) 2004-01-07

Similar Documents

Publication Publication Date Title
ECSP003652A (es) TRATAMIENTO DE COMBINACION CON I1-1ra Y COMPUESTOS QUE INHIBEN EL PROCESAMIENTO Y LA LIBERACION DE I1-1
UY26296A1 (es) Tratamiento medicamentoso del síndrome de piernas inquietas
ES2146300T3 (es) Utilizacion de composiciones antihelminticas para el tratamiento de infecciones causadas por anoplocephala perfoliata en equidos.
MX9203444A (es) Medicamentos.
ES2188177T3 (es) Composicion para la prevencion y/o el tratamiento de la osteoporosis y las alteraciones debidas al sindrome menopausico, que comprende propionil-l-carnitina y genisteina.
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
CL2012000348A1 (es) Metodo para tratar o reducir la gravedad de la osteoporosis u osteopenia en un paciente que comprende administrarle el compuesto n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida o una sal del mismo; composicion farmaceutica.
CO5160262A1 (es) Formulaciones farmaceuticas de liberacion controlada
AR020015A1 (es) Composiciones de celecoxib
AR109263A2 (es) Composición que comprende moxidectina
CO5160320A1 (es) Metodos y composiciones para la prevencion de tolerancia a medicamentos das.
CL2009001279A1 (es) Compuestos derivados de nociceptina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor (sol. divisional 2103-03).
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
ES2196190T3 (es) Inhibidores de metaloproteinasas matriciales, con hidroxamato bifenlico.
ATE333896T1 (de) Vaskularisierungsinhibitoren
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
ES2083597T3 (es) Preparacion farmaceutica para el tratamiento del tiempo de coagulacion prolongado.
SV2002000235A (es) Composiciones farmaceuticas que comprenden valdecoxib
PE20010642A1 (es) Combinacion de pramipexol y clonidina para el tratamiento del sindrome de piernas inquietas
CO5570661A2 (es) Combinaciones que comprenden inhibidores de cox-2 y aspirina
AR043660A1 (es) El tratamiento de la enfermedad de alzheimer
AR021690A1 (es) Empleo de inhibidores del canal de ktq1 para la preparacion de un medicamento para el tratamiento de enfermedades, que son provocadas por helmintos yectoparasitos.
AR046402A1 (es) Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio
AR034975A1 (es) Metodo para el tratamiento del insomnio primario
AR053650A1 (es) Formas de dosificacion oral solidas que contienen una dosis baja de estradiol